The leading US diabetes charity, the American Diabetes Association (ADA), has partnered with Entelos, Inc. to launch a new simulation tool called Realab.
The tool gives direct Internet access to Entelos models of type 1 diabetes. In theory, this gives scientists and clinicians a new level of ability to investigate onset, progression and treatment of diabetes.
Researchers using Realab will be able to conduct simulated drugs, drug combinations, dose levels, therapeutic targets, pathways and functions. The researcher submits a request to Realab, which then provides data within 24 hours. Experts can therefore conduct virtual experiments.
The type 1 diabetes Physiolab platform, a mathematical model of the non-obese mouse with type 1 diabetes, informs the Realab software . Richard Kah, the chief scientific and medical officer at the ADA reportedly commented: “The ADA is committed to finding new treatments and, ultimately, a cure for diabetes. Realab will help researchers by providing them with direct access to Entelos’ cutting-edge simulation technology via the web and make a big impact on both preclinical and clinical programs in type 1 diabetes, which primarily affects children and young adults. We are excited to unveil this innovative approach to finding better therapies in partnership with Entelos.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…